BEAM
HealthcareBeam Therapeutics Inc.
$26.84
$-0.30 (-1.11%)
Jan 5, 2026
Price History (1Y)
Analysis
Beam Therapeutics Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $2.72 billion and annual revenues of $55.70 million, it has established itself as a significant player in its industry. The company's workforce comprises 510 employees. Financially, Beam Therapeutics faces significant challenges. Its net income for the trailing twelve months (TTM) stands at -$414,643,008, indicating substantial losses. The company's operating margin is reported at -1307.6%, while its profit margin is 0.0%. Additionally, it has generated negative free cash flow of $-166,764,128 and holds a debt-to-equity ratio of 15.68. On the other hand, Beam Therapeutics possesses significant liquidity with a cash balance of $1.07 billion. Beam Therapeutics' valuation metrics are somewhat concerning. Its forward price-to-earnings (P/E) ratio is -5.89, while its price-to-sales ratio stands at 48.90. The company's debt-to-equity ratio is relatively low compared to other biotechnology firms in the sector. However, it has been experiencing a decline in revenue growth year-over-year (YoY), with a reported rate of -32.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $2.72B
- P/E Ratio
- N/A
- 52-Week High
- $35.25
- 52-Week Low
- $13.53
- Avg Volume
- 2.11M
- Beta
- 2.07
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 510